AVDL

FT218

Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy

Stage (next event)

Expected Date

NDA Filing

December 2020

Catalyst Info & Data Links

TITLE: FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy NDA Filing


WHAT IS THE NEXT CATALYST EVENT?

  • NDA Filing


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • December 2020


PRIOR DATA/EVENTS

PRESS RELEASES

MECHANISM OF ACTION 

  • FT218 is an investigational, once-nightly formulation of Micropump™ controlled-release (CR) sodium oxybate. 

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon